BriaCell Therapeutics Corp. (BCTX) Stock Score, Valuation & Financial Research

BriaCell Therapeutics Corp. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BCTX

BriaCell Therapeutics Corp. does not currently have a complete Wall Street Score. The stored market price is USD 4.02. These figures are a research snapshot, not a buy or sell recommendation.

What BriaCell Therapeutics Corp. does

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

Company business and revenue

Research reporting period: 2025-07-31. A research update is not a new financial filing.

How the company makes money

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on the research and development of novel immunotherapies for cancer, funded through capital raises and equity financing as it advances its product candidates through clinical trials.

Products and services

  • The company is developing Bria-IMT, a targeted immunotherapy for metastatic breast cancer, and Bria-OTS, a personalized off-the-shelf immunotherapy platform for various cancers.

Business relationships and partnerships

  • Memorial Sloan Kettering Cancer Center (MSK) — A collaboration with MSK’s Therapeutics Accelerator program focused on the Bria-OTS+ platform. Source

Business strengths to evaluate

  • Clinical-stage pipeline of novel immunotherapies Source

Business risks and research considerations

  • Substantial doubt about ability to continue as a going concern Source
  • Pre-revenue clinical stage status Source
  • High dependency on key personnel Source

Sources: Company research source · Memorial Sloan Kettering Cancer Center (MSK)

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BCTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.02
Market capitalization:
34.97M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -37.06M
Free cash flow:
USD -39.07M
Cash:
USD 6.88M
Total debt:
USD 0.00
EPS:
USD -13.84

What stands out

  • Free cash flow is USD -39.07M, negative for the stored period.
  • The balance sheet shows USD 6.88M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 6.88M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BCTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BCTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BCTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BCTX to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BCTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research BCTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.